Analyst Price Forecast Suggests 128.93% Upside
As of June 2, 2023, the average one-year price target for Sigilon Therapeutics is 51.51. The forecasts range from a low of 7.07 to a high of $95.55. The average price target represents an increase of 128.93% from its latest reported closing price of 22.50.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sigilon Therapeutics is 11MM, a decrease of 23.34%. The projected annual non-GAAP EPS is -1.29.
What is the Fund Sentiment?
There are 53 funds or institutions reporting positions in Sigilon Therapeutics. This is an increase of 1 owner(s) or 1.92% in the last quarter. Average portfolio weight of all funds dedicated to SGTX is 0.01%, an increase of 73.02%. Total shares owned by institutions increased in the last three months by 1.20% to 17,844K shares. The put/call ratio of SGTX is 0.17, indicating a bullish outlook.
What are Other Shareholders Doing?
Flagship Pioneering holds 10,370K shares representing 31.88% ownership of the company. No change in the last quarter.
Canada Pension Plan Investment Board holds 1,485K shares representing 4.57% ownership of the company. No change in the last quarter.
Cercano Management holds 885K shares representing 2.72% ownership of the company. No change in the last quarter.
Harbourvest Partners holds 741K shares representing 2.28% ownership of the company. No change in the last quarter.
BlackRock Health Sciences Trust II holds 565K shares representing 1.74% ownership of the company. No change in the last quarter.
Sigilon Therapeutics Background Information
(This description is provided by the company.)
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
- Lilly to Acquire Sigilon Therapeutics
- Form 10-Q
- SIGILON THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization
- SIGILON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 S
- Form 10-K
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.